Accelerating the development of new therapies

The companies currently hosted within the Institute span a wide range of sectors and technologies.
However they are all united by a common goal—improving patient care.


Cardiac arrhythmia affects 2.5 million Americans. Left untreated it can lead to stroke and heart failure. CyberHeart has developed the first non-invasive, automated ablation treatment for such arrhythmias.

Enspectra Health

Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.

G-Tech Medical

Up to 60 million individuals in the U.S. suffer from debilitating gastrointestinal disorders. G-Tech Medical is developing a wearable technology aimed at improving outcomes and reducing costs by non-invasively monitoring gastrointestinal tract activity.

Healyx Labs

More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, if not eliminate, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.


Over half a million patients with aging valves and vessels undergo structural repairs of the cardiovascular system each year. Though traditionally open surgeries have become less invasive, physicians are still faced with the challenge of closing large-bore access sites in the femoral artery. Lume is enabling safe and effective closure of these access sites to complement the growing incidence of large-bore endovascular procedures.

Materna Medical

Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed two therapeutic dilation devices: the first is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time. The second is helping treat pelvic pain and dyspareunia.


Each day, more than 1,100 babies born in the U.S. require assistance breathing. MedicalCue has developed a bedside device that guides medical teams through newborn resuscitation, greatly increasing the accuracy of care delivered. The Cue platform analyzes vital patient information and determines the best path for patient care.


Fifteen million Americans suffer from hyperhidrosis, also known as excessive sweating. This condition can dramatically affect quality of life in both social and professional settings. palmm is developing a simple, at-home treatment for hyperhidrosis, initially focusing on the hands.

Radial Medical

Each year, over 80 million people in the U.S. could benefit from Radial’s smart, wearable compression therapy system for the prevention of deep vein thrombosis, treating restless leg syndrome and healing venous leg ulcers. Radial’s intelligent compression technology combines best-in-class adjustable compression therapy, continuous monitoring, disease detection capability and digital patient engagement.

Raydiant Oximetry

Nearly half of all C-sections performed in the U.S. are retrospectively deemed unnecessary. Raydiant is developing a non-invasive sensor to monitor fetal oxygenation during labor, with the aim to improve the diagnosis of fetal distress and reduce the rate of unwarranted C-sections.